GH Cochin - Broca - Hôtel-Dieu CIC BT505
Welcome,         Profile    Billing    Logout  
 18 Trials 
25 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Launay, Odile
PREV-HOSPIT, NCT06822907: Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

Not yet recruiting
4
1052
Europe
Early intervention, Delayed intervention
Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France
Acute Febrile Illness, Pneumococcal Infections
01/27
01/28
COVID-BCG, NCT04384549 / 2020-001678-31: Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers

Recruiting
3
1120
Europe
BCG GROUP, Experimental GROUP, PLACEBO GROUP, Control GROUP
Assistance Publique - Hôpitaux de Paris
Infection, Viral, Agent as Cause of Disease Classified Elsewhere
02/21
02/21
COVIBOOST 2, NCT05405283 / 2021-004550-33: Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults

Active, not recruiting
3
189
Europe
2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Assistance Publique - Hôpitaux de Paris, IREIVAC/COVIREIVAC Network
COVID-19 Vaccines
07/22
07/23
COVIBOOST, NCT05124171 / 2021-004550-33: Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination

Active, not recruiting
3
247
Europe
BNT162b2, pfzer/BioNTech, mARN vaccine,, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Assistance Publique - Hôpitaux de Paris, COVIREIVAC
COVID-19, Vaccine Reaction
12/22
12/22
FLUO, NCT05409612 / 2021-002691-39: Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients

Completed
3
206
Europe
Supemtek®, Vaxigriptetra®
Assistance Publique - Hôpitaux de Paris, Sanofi Pasteur, a Sanofi Company, Hospices Civils de Lyon
Morbid Obesity, Severe Obesity
04/23
10/23
CoviBOOST 2, NCT05749926 / 2022-002715-38: Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine

Active, not recruiting
3
248
Europe
Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech), VidPrevtyn® Beta vaccine (Sanofi/GSK)
Assistance Publique - Hôpitaux de Paris, IREIVAC/COVIREIVAC Network
Vaccine Reaction, COVID-19
07/23
07/24
SPLEMENGO, NCT04166656: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
3
84
Europe
Trumenba®, Bexsero®
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, Innovative clinical research in vaccinologie (I-REIVAC), Institut Pasteur
Splenectomy
09/28
10/28
NCT05569239: Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

Not yet recruiting
2b
1500
NA
OVX836 480µg, Saline Solution
Osivax, Hôpital Cochin, Clinact
Influenza
12/23
07/24
CoviCompareM, NCT04748471: Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)

Not yet recruiting
2
180
NA
mRNA-1273
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Prevention of COVID19
07/21
01/23
CoviCompMali, NCT05409261: Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Active, not recruiting
2
200
RoW
Ad26.COV2.S, Janssen, Johnson&Johnson
ANRS, Emerging Infectious Diseases, CEPI, Innovative clinical research network in vaccinology (IREIVAC), Institut National de la Santé Et de la Recherche Médicale, France, APHP, Center for Vaccine Development - Mali
COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
09/22
03/25
SPLENEVAC-2, NCT03873727 / 2018-003068-29: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.

Active, not recruiting
2
39
Europe
Prevenar13 (PCV13) and Pneumovax (PPS23), Placebo / Pneumovax (PPS23), Blood sample
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, I-REIVAC Innovative Clinical Research Network In Vaccinology
Splenectomised Patients
06/23
06/24
CovicompareG, NCT05409300: Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea

Active, not recruiting
2
200
RoW
BBIBP-CorV, Sinopharm
ANRS, Emerging Infectious Diseases, CEPI, Alliance for International Medical Action, Centre National de Formation et de Recherche en Sante Rurale, Institut National de la Santé Et de la Recherche Médicale, France, APHP, Agence Nationale de Sécurité Sanitaire de la Guinée (ANSS Guinée), Innovative clinical research network in vaccinology (IREIVAC)
COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection, Healthy Volunteer
08/23
02/25
NCT06255626: Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

Recruiting
1/2
215
Europe
CD40.RBDv vaccin (SARS-Cov2 Vaccin), COVID-19 mRNA vaccine
ANRS, Emerging Infectious Diseases, Vaccine Research Institute (VRI), France, EnnoDc (previously known as LinKinVax)
COVID-19
09/25
09/25
MUCOBOOST, NCT06821126: Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults

Not yet recruiting
1/2
238
Europe
LVT-001, Cormirnaty
ANRS, Emerging Infectious Diseases, University Hospital, Tours (Cosponsor), UMS 54 MART, INSERM CIC 1415, LovalTech, INSERM U1259 MAVIVHe, BioMAP - UMR ISP 1282 - Tours University - INRAE, Virology unit, University Hospital, Tours, I-REIVAC Innovative Clinical Research Network In Vaccinology
Healthy
10/26
03/28
LymphoBOOST, NCT05951920: Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.

Recruiting
1
12
Europe
Lymph node aspiration / Blood sampling
Assistance Publique - Hôpitaux de Paris
COVID-19
07/23
09/23
NCT04842682: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

Completed
1
72
Europe
Solo 0.3 group, Solo 1 group, Solo 3 group, Combi 0.3 group, Combi 1 group, Combi 3 group, Late boost CD40 alone, Late boost CD40 adjuvanted
ANRS, Emerging Infectious Diseases
Healthy Adults
11/24
11/24
NCT06128382: First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

Completed
1
48
Europe
OVX033, Saline solution
Osivax, CIC 1417 Cochin Pasteur Hôpital Cochin Paris France
Coronavirus
07/24
11/24
NCT04844775: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Active, not recruiting
1
68
Europe
Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L, DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above), DNA-HIV-PT123 4mg and CN54gp140/MPLA-L
ANRS, Emerging Infectious Diseases, Medical Research Council, Henri Mondor University Hospital, Chelsea and Westminster Hospital, UK, EuroVacc Foundation, European Commission, Swiss Government, University College London Hospitals, Imperial College London, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Healthy Adults
09/24
09/24
SYNACTHIV, NCT05230368: Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load

Recruiting
1
15
Europe
Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2, Romidepsin cycle 2, Decitabine cycle 3, Romidepsin cycle 3, Decitabine cycle 4, Romidepsin cycle 4
ANRS, Emerging Infectious Diseases, INSERM SC10-US19
HIV-1-infection, Subtype b
04/26
04/26
ARNCOMBI, NCT04900467 / 2021-002174-52: Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine

Active, not recruiting
N/A
418
Europe
Pfizer, Moderna
Assistance Publique - Hôpitaux de Paris, COVIREIVAC
Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose
07/21
01/22
PREDIACC, NCT04208711: Role of PLA2G1B During HIV Infection

Recruiting
N/A
15
Europe
biological sample
Diaccurate SAS, CIC 1417 Cochin-Pasteur
HIV Infections
03/22
03/22
FLUVAC EV-03, NCT02027233: Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults

Completed
N/A
6173
Europe
nasopharyngeal sample
Institut National de la Santé Et de la Recherche Médicale, France
Severe Acute Respiratory Infection
12/22
12/22
COV-POPART, NCT04824651: Covid-19 Vaccine Cohort in Specific Populations

Active, not recruiting
N/A
6920
Europe
COVID-19 vaccine
ANRS, Emerging Infectious Diseases, Institut National de la Santé Et de la Recherche Médicale, France
Immune Deficiency
06/24
06/24
NCT05450770: Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination

Not yet recruiting
N/A
60
NA
Yellow fever vaccination (STAMARIL)
ANRS, Emerging Infectious Diseases, Saint-Louis Hospital, Paris, France, Bichat Hospital, Hôpital Cochin
HIV Infections, Yellow Fever
11/24
11/24
M-BOOST-FR, NCT06885853: Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

Not yet recruiting
N/A
90
Europe
Assistance Publique - Hôpitaux de Paris
Monkeypox
09/26
09/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Launay, Odile
PREV-HOSPIT, NCT06822907: Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

Not yet recruiting
4
1052
Europe
Early intervention, Delayed intervention
Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France
Acute Febrile Illness, Pneumococcal Infections
01/27
01/28
COVID-BCG, NCT04384549 / 2020-001678-31: Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers

Recruiting
3
1120
Europe
BCG GROUP, Experimental GROUP, PLACEBO GROUP, Control GROUP
Assistance Publique - Hôpitaux de Paris
Infection, Viral, Agent as Cause of Disease Classified Elsewhere
02/21
02/21
COVIBOOST 2, NCT05405283 / 2021-004550-33: Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults

Active, not recruiting
3
189
Europe
2nd booster with Comirnaty® (Pfizer-BioNTech), CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Assistance Publique - Hôpitaux de Paris, IREIVAC/COVIREIVAC Network
COVID-19 Vaccines
07/22
07/23
COVIBOOST, NCT05124171 / 2021-004550-33: Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination

Active, not recruiting
3
247
Europe
BNT162b2, pfzer/BioNTech, mARN vaccine,, CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK, CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Assistance Publique - Hôpitaux de Paris, COVIREIVAC
COVID-19, Vaccine Reaction
12/22
12/22
FLUO, NCT05409612 / 2021-002691-39: Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients

Completed
3
206
Europe
Supemtek®, Vaxigriptetra®
Assistance Publique - Hôpitaux de Paris, Sanofi Pasteur, a Sanofi Company, Hospices Civils de Lyon
Morbid Obesity, Severe Obesity
04/23
10/23
CoviBOOST 2, NCT05749926 / 2022-002715-38: Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine

Active, not recruiting
3
248
Europe
Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech), VidPrevtyn® Beta vaccine (Sanofi/GSK)
Assistance Publique - Hôpitaux de Paris, IREIVAC/COVIREIVAC Network
Vaccine Reaction, COVID-19
07/23
07/24
SPLEMENGO, NCT04166656: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
3
84
Europe
Trumenba®, Bexsero®
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, Innovative clinical research in vaccinologie (I-REIVAC), Institut Pasteur
Splenectomy
09/28
10/28
NCT05569239: Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

Not yet recruiting
2b
1500
NA
OVX836 480µg, Saline Solution
Osivax, Hôpital Cochin, Clinact
Influenza
12/23
07/24
CoviCompareM, NCT04748471: Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)

Not yet recruiting
2
180
NA
mRNA-1273
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
Prevention of COVID19
07/21
01/23
CoviCompMali, NCT05409261: Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

Active, not recruiting
2
200
RoW
Ad26.COV2.S, Janssen, Johnson&Johnson
ANRS, Emerging Infectious Diseases, CEPI, Innovative clinical research network in vaccinology (IREIVAC), Institut National de la Santé Et de la Recherche Médicale, France, APHP, Center for Vaccine Development - Mali
COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
09/22
03/25
SPLENEVAC-2, NCT03873727 / 2018-003068-29: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.

Active, not recruiting
2
39
Europe
Prevenar13 (PCV13) and Pneumovax (PPS23), Placebo / Pneumovax (PPS23), Blood sample
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, I-REIVAC Innovative Clinical Research Network In Vaccinology
Splenectomised Patients
06/23
06/24
CovicompareG, NCT05409300: Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea

Active, not recruiting
2
200
RoW
BBIBP-CorV, Sinopharm
ANRS, Emerging Infectious Diseases, CEPI, Alliance for International Medical Action, Centre National de Formation et de Recherche en Sante Rurale, Institut National de la Santé Et de la Recherche Médicale, France, APHP, Agence Nationale de Sécurité Sanitaire de la Guinée (ANSS Guinée), Innovative clinical research network in vaccinology (IREIVAC)
COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection, Healthy Volunteer
08/23
02/25
NCT06255626: Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

Recruiting
1/2
215
Europe
CD40.RBDv vaccin (SARS-Cov2 Vaccin), COVID-19 mRNA vaccine
ANRS, Emerging Infectious Diseases, Vaccine Research Institute (VRI), France, EnnoDc (previously known as LinKinVax)
COVID-19
09/25
09/25
MUCOBOOST, NCT06821126: Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults

Not yet recruiting
1/2
238
Europe
LVT-001, Cormirnaty
ANRS, Emerging Infectious Diseases, University Hospital, Tours (Cosponsor), UMS 54 MART, INSERM CIC 1415, LovalTech, INSERM U1259 MAVIVHe, BioMAP - UMR ISP 1282 - Tours University - INRAE, Virology unit, University Hospital, Tours, I-REIVAC Innovative Clinical Research Network In Vaccinology
Healthy
10/26
03/28
LymphoBOOST, NCT05951920: Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.

Recruiting
1
12
Europe
Lymph node aspiration / Blood sampling
Assistance Publique - Hôpitaux de Paris
COVID-19
07/23
09/23
NCT04842682: Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

Completed
1
72
Europe
Solo 0.3 group, Solo 1 group, Solo 3 group, Combi 0.3 group, Combi 1 group, Combi 3 group, Late boost CD40 alone, Late boost CD40 adjuvanted
ANRS, Emerging Infectious Diseases
Healthy Adults
11/24
11/24
NCT06128382: First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

Completed
1
48
Europe
OVX033, Saline solution
Osivax, CIC 1417 Cochin Pasteur Hôpital Cochin Paris France
Coronavirus
07/24
11/24
NCT04844775: A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

Active, not recruiting
1
68
Europe
Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L, DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above), DNA-HIV-PT123 4mg and CN54gp140/MPLA-L
ANRS, Emerging Infectious Diseases, Medical Research Council, Henri Mondor University Hospital, Chelsea and Westminster Hospital, UK, EuroVacc Foundation, European Commission, Swiss Government, University College London Hospitals, Imperial College London, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Healthy Adults
09/24
09/24
SYNACTHIV, NCT05230368: Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load

Recruiting
1
15
Europe
Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2, Romidepsin cycle 2, Decitabine cycle 3, Romidepsin cycle 3, Decitabine cycle 4, Romidepsin cycle 4
ANRS, Emerging Infectious Diseases, INSERM SC10-US19
HIV-1-infection, Subtype b
04/26
04/26
ARNCOMBI, NCT04900467 / 2021-002174-52: Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine

Active, not recruiting
N/A
418
Europe
Pfizer, Moderna
Assistance Publique - Hôpitaux de Paris, COVIREIVAC
Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose
07/21
01/22
PREDIACC, NCT04208711: Role of PLA2G1B During HIV Infection

Recruiting
N/A
15
Europe
biological sample
Diaccurate SAS, CIC 1417 Cochin-Pasteur
HIV Infections
03/22
03/22
FLUVAC EV-03, NCT02027233: Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults

Completed
N/A
6173
Europe
nasopharyngeal sample
Institut National de la Santé Et de la Recherche Médicale, France
Severe Acute Respiratory Infection
12/22
12/22
COV-POPART, NCT04824651: Covid-19 Vaccine Cohort in Specific Populations

Active, not recruiting
N/A
6920
Europe
COVID-19 vaccine
ANRS, Emerging Infectious Diseases, Institut National de la Santé Et de la Recherche Médicale, France
Immune Deficiency
06/24
06/24
NCT05450770: Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination

Not yet recruiting
N/A
60
NA
Yellow fever vaccination (STAMARIL)
ANRS, Emerging Infectious Diseases, Saint-Louis Hospital, Paris, France, Bichat Hospital, Hôpital Cochin
HIV Infections, Yellow Fever
11/24
11/24
M-BOOST-FR, NCT06885853: Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

Not yet recruiting
N/A
90
Europe
Assistance Publique - Hôpitaux de Paris
Monkeypox
09/26
09/27

Download Options